O1. EGFR, EML4-ALK and ROS 1 testing in Austrian patients with NSCLC: a multicentre study

Background Mutations in epidermal growth factor receptor (EGFR), EML4-ALK and ROS1 can clearly impact the treatment decisions for patients with non-small cell lung cancer (NSCLC). The incidence of these mutations in Austria is unknown. The aim of the study was to evaluate the prevalence of EGFR, EML4-ALK and ROS1 mutations in Austrian patients with NSCLC.